### Longitudinal Patient Data - France

**First published:** 01/02/2024

**Last updated:** 17/10/2024

**Data source** 



**Primary care medical records** 

### Administrative details

### Administrative details

#### **PURI**

https://redirect.ema.europa.eu/resource/1111149

#### **Data source ID**

1111149

#### Data source acronym

LPD FRA

#### **Data holder**

**IQVIA** 

### **Data source type**

Primary care medical records

### Main financial support

Funding by own institution

Funding from industry or contract research

### **Care setting**

Primary care - GP, community pharmacist level

Primary care - specialist level (e.g. paediatricians)

### **Data source qualification**

If the data source has successfully undergone a formal qualification process (e.g., from the EMA, ISO or other certifications), this should be described.

No

#### **Data source website**

https://www.iqvia.com/solutions/real-world-evidence/real-world-data-and-insights

### Contact details

### Sarah Seager



sarah.seager@iqvia.com

### Data source regions and languages

#### **Data source countries**

France

### **Data source languages**

French

### Data source establishment

#### Data source established

15/06/1991

#### Data source time span

First collection: 01/01/2012

The date when data started to be collected or extracted.

### **Publications**

### Data source publications

Analysis of Dual Combination Therapies Used in Treatment of Hypertension in a Multinational Cohort. JAMA Netw Open. 2022;5(3):e223877. doi:10.1001/jamanetworkopen.2022.3877.

Rates of Antipsychotic Drug Prescribing Among People Living With Dementia During the COVID-19 Pandemic. AMA Psychiatry. 2023 Mar 1;80(3):211-219.

Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID -19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries. Pharmacoepidemiology and Drug Safety (2022). 10.1002/pds.5419.

### **Studies**

## List of studies that have been conducted using the data source

Drug Utilisation Study for Olodaterol

Drug Utilization Study of Thiocolchicoside (TCC) containing medicinal products for systemic use in France and Italy: an electronic medical records databases study

Drug Utilisation Study of conjugated oestrogens/bazedoxifene (CE/BZA) in the European Union (EU)

Study of exposure and use patterns of alternatives to ranitidine-containing medicines in patients treated with ranitidine (Ranitidine)

Drug utilization of Intrarosa (6.5 mg prasterone pessary) in European Countries (ERC-243)

A Retrospective Cohort Study for Estimating Incidence Rates of Infusion Site Events for ABBV-951 for the Treatment of Advanced Parkinson's Disease

An Observational Study Assessing the Long-term Risk of Non-Melanoma Skin Cancer (NMSC) Among New Users of OpzeluraTM (Ruxolitinib) Cream in a Vitiligo Patient Population: Post-Authorization Safety Study (PASS)

### Data elements collected

## The data source contains the following information

#### **Disease information**

Does the data source collect information with a focus on a specific disease? This might be a patient registry or other similar initiatives.

No

#### Rare diseases

Are rare diseases captured? In the European Union a rare disease is one that affects no more than 5 people in 10,000.					
No					
Pregnancy and/or neonates					
Does the data source collect information on pregnant women and/or neonatal subpopulation (unde					
28 days of age)?					
Yes					
Hospital admission and/or discharge					
No					
ICU admission					
Is information on intensive care unit admission available?					
No					
Cause of death					
Captured					
Cause of death vocabulary					
Not coded (Free text)					
Prescriptions of medicines					
Captured					
Prescriptions vocabulary					
RxNorm					
Dispensing of medicines					
Captured					
•					

Dispensing vocabulary	
other	
RxNorm	
Dispensing vocabulary, other	
CVX	
Advanced therapy medicinal products (ATMP)	
Is information on advanced therapy medicinal products included? A medicinal product for hun	nan
use that is either a gene therapy medicinal product, a somatic cell therapy product or a tissue	j
engineered products as defined in Regulation (EC) No 1394/2007 [Reg (EC) No 1394/2007 Art	1(1)].
No	
Contraception	
Is information on the use of any type of contraception (oral, injectable, devices etc.) available	?
Yes	
Indication for use  Does the data source capture information on the therapeutic indication for the use of medicin products?  Captured	al
Indication vocabulary	
SNOMED	
Medical devices	
Is information on medicinal devices (e.g., pens, syringes, inhalers) available?	
No	
Administration of vaccines	
No	

#### **Procedures**

Does the data source capture information on procedures (e.g., diagnostic tests, therapeutic, surgical interventions)?

Captured

### **Procedures vocabulary**

**SNOMED** 

#### **Healthcare** provider

Is information on the person providing healthcare (e.g., physician, pharmacist, specialist) available? The healthcare provider refers to individual health professionals or a health facility organisation licensed to provide health care diagnosis and treatment services including medication, surgery and medical devices.

Yes

#### **Clinical measurements**

Is information on clinical measurements (e.g., BMI, blood pressure, height) available?

Yes

#### **Genetic data**

Are data related to genotyping, genome sequencing available?

Not Captured

#### Biomarker data

Does the data source capture biomarker information? The term "biomarker" refers to a broad subcategory of medical signs (objective indications of medical state observed from outside the patient), which can be measured accurately and reproducibly. For example, haematological assays, infectious disease markers or metabolomic biomarkers.

Captured

### Biomarker data vocabulary

Other

#### Biomarker vocabulary, other

LOINC, SNOMED

### **Patient-reported outcomes**

Is information on patient-reported outcomes (e.g., quality of life) available?

No

### Patient-generated data

Is patient-generated information (e.g., from wearable devices) available?

Yes

#### Units of healthcare utilisation

Are units of healthcare utilisation (e.g., number of visits to GP per year, number of hospital days) available or can they be derived? Units of healthcare utilisation refer to the quantification of the use of services for the purpose of preventing or curing health problems.

Yes

### Unique identifier for persons

Are patients uniquely identified in the data source?

Yes

### **Diagnostic codes**

Captured

### Diagnosis / medical event vocabulary

**SNOMED** 

### **Medicinal product information**

Captured

Medicinal product information collected				
Active ingredient(s)				
Brand name				
Package size				
Route of administration				
Strength				
Medicinal product vocabulary				
RxNorm				
Quality of life measurements				
Captured				
Quality of life measurements vocabulary				
Not coded (Free text)				
Lifestyle factors				
Captured				
Lifestyle factors				
Alcohol use				
Other				
Tobacco use				
Sociodemographic information				
Captured				
Sociodemographic information collected				
Gender				

Marital status

Other

### Quantitative descriptors

### Population Qualitative Data

#### **Population age groups**

Paediatric Population (< 18 years)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Elderly (≥ 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated percentage of the population covered by the data source in the catchment area

4%

Description of the population covered by the data source in the catchment area whose data are not collected (e.g., people who are registered only for private care)

General population

### Family linkage

## Family linkage available in the data source permanently or can be created on an ad hoc basis

Ad hoc

### **Population**

### **Population size**

17600000

### **Active population size**

3700000

### Population by age group

Age group	Population size	Active population size
Paediatric Population (< 18 years)	2784513	570209
Children (2 to < 12 years)	1625765	326914
Adolescents (12 to < 18 years)	822068	182539
Adults (18 to < 46 years)	6327024	1118839
Adults (46 to < 65 years)	4376782	1000914
Elderly (≥ 65 years)	3995905	1030457
Adults (65 to < 75 years)	2027632	523641
Adults (75 to < 85 years)	1317656	352820

Age group	Populationsize	Active populationsize
Adults (85 years and over)	650617	153996

### Median observation time

Median time (years) between first and last available records for unique individuals captured in the data source

177.00

Median time (years) between first and last available records for unique active individuals (alive and currently registered) capt

1083.00

### Data flows and management

### Access and validation

#### **Governance details**

Documents or webpages that describe the overall governance of the data source and processes and procedures for data capture and management, data quality check and validation results (governing data access or utilisation for research purposes).

https://www.pharmacoepi.org/resources/policies/guidelines-08027/

#### **Biospecimen access**

No

### Access to subject details

Can individual patients/practitioners/practices included in the data source be contacted?

No

### **Description of data collection**

Anonymized patient records collected from patient management software used by GPs to document patients' clinical records

### **Event triggering registration**

#### Event triggering registration of a person in the data source

Practice registration

### Event triggering de-registration of a person in the data source

Death

**Emigration** 

Loss to follow up

Practice deregistration

### Event triggering creation of a record in the data source

Physician encounter

### Data source linkage

#### Linkage

Is the data source described created by the linkage of other data sources (prelinked data source) and/or can the data source be linked to other data source on an ad-hoc basis?

No

## Data management specifications that apply for the data source

#### **Data source refresh**

Quarterly

### Informed consent for use of data for research

Not Required

### Possibility of data validation

Can validity of the data in the data source be verified (e.g., access to original medical charts)?

No

### **Data source preservation**

Are records preserved in the data source indefinitely?

No

### **Data source preservation length (years)**

10 years

### **Approval for publication**

Is an approval needed for publishing the results of a study using the data source?

No

### **Data source last refresh**

01/12/2022

### Common Data Model (CDM) mapping

### **CDM** mapping

Has the data source been converted (ETL-ed) to a common data model?

Yes

### **CDM Mappings**

# OMOP CDM website

https://www.ohdsi.org/Data-standardization/

### **Data source ETL CDM version**

5.3.1

### **Data source ETL frequency**

4,00 months

**CDM** name

### **Data source ETL status**

Completed